Topical nonsteroidal anti-inflammatory drug effect on patients with pseudoexfoliation syndrome during cataract surgery
Phase 3
Recruiting
- Conditions
- Anterior segment inflammation and complications after cataract surgery in patients with pseudoexfoliation syndrome.Age-related cataract
- Registration Number
- IRCT20160919029871N3
- Lead Sponsor
- Guilan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Having Significant cataract (grade 3 and higher) and clinical signs of PEX.
The patient should not be used systemic or inhaled NSAIDs within 1 week before surgery and the patients should not use the inhaled or systemic corticosteroids within 15 days after surgery
Exclusion Criteria
Having known hypersensitivity to any components of the NSAIDs
uncontrolled chronic ocular or systemic inflammatory disease; a history of eye trauma and any retinal and macular disease, any intraocular complication during surgery (vitreous loss)
The patient who must be treated with systemic anti-inflammatory medications for extensive inflammation following cataract surgery
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of subjects with anterior chamber inflammation based on cell count (CELL) and percentage of subjects with anterior chamber inflammation based on protein content based on the rating of the San-working Group (0 to 4 degrees). Timepoint: 1, 3, 7 and 30 days after surgery. Method of measurement: Clinical examination.
- Secondary Outcome Measures
Name Time Method The degree of opacity of the anterior capsule (ACO) (grade 0-4) and degree of opacity of the posterior capsule (PCO) (grade 0-4). Timepoint: 1,3,6 months postoperatively. Method of measurement: photo slit examination.